: iStockAnalyst.com Symbols Feed

A Busy Month For Immunogen (Part II)

Thu, 03 Dec 2009 21:03:11 GMT

At ASH 2009, Immunogen (IMGN) and its partners will present clinical data on three compounds: Sanofi-Aventis’ (SNY) SAR3419, Immunogen’s IMGN901 and Biotest’s BT-062.[More...]

Invest In HealthCare!

Tue, 01 Dec 2009 16:52:08 GMT

In 3 of the past 4 market rebounds since 1982, equity gains slowed to a single digit pace in the 2nd year, after the initial rally. Now dividend stocks have extra appeal because they offer a tempting alternative to CDs which pay virtually no interest at all, and long term bonds which pay a little bit more but leave you at the mercy of inflation. Established value companies in stable industries have usually proven a better long-term investment. Before S&P cut Pfizer (PFE) ratings to 'AA' from 'AAA' on Oct 16, 2009, there were 5 companies with AAA credit ratings: Automated Data Processing (ADP), Johnson & Johnson (JNJ), ExxonMobil (XOM) and Microsoft (MSFT). In other words, 2 out of 5 were healthcare companies.[More...]

Most Active Stock Options November 18, 2009 & Trading Activity

Wed, 18 Nov 2009 20:38:01 GMT

The top ten most active option contracts traded today were: 1. S&P 500 SPDR (SPY) November 111 Put Options 2. S&P 500 SPDR November 111 Call Options[More...]

Options Intelligence Report: Mead Johnson And Bristol Myers Split Inspires Option Traders

Mon, 16 Nov 2009 19:53:08 GMT

Today's tickers: MJN, BMY, FTR & FDO[More...]

Investing In The Biotech Sector: Here’s An Easy Way To Profit From Biotech Stocks

Wed, 11 Nov 2009 14:39:06 GMT

Investing in the Biotech Sector: Here’s An Easy Way to Profit from Biotech Stocks by Marc Lichtenfeld, Healthcare Expert Wednesday, November 11, 2009: Issue #1135 Investing in the biotech sector can be risky – no doubt about that.[More...]

Big Pharma And Biotech - Industry Outlook

Mon, 09 Nov 2009 21:58:02 GMT

The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses.[More...]

Sanofi-Aventis to Create China Vitamin JV with Minsheng

Mon, 26 Oct 2009 16:40:37 GMT

Sanofi-Aventis (NYSE: SNY) signed a letter of intent last Saturday to establish a joint venture with Minsheng Pharmaceutical Group of Hangzhou. The JV will focus on OTC vitamin and mineral products. Minsheng already produces the best selling product in the sector: 21-Super Vita multivitamin-multimineral tablets. For Sanofi-Aventis, the JV will provide an entry into China’s OTC market. Sanofi-Aventis will have the majority share in the JV.[More...]

Healthcare M&A Activitiy: Three Healthcare Small Caps Primed For Takeovers

Thu, 22 Oct 2009 16:22:43 GMT

With the healthcare debate still raging in Washington, this should shock you… Healthcare mergers and acquisition (M&A) activity is at an all-time high.[More...]

Celldex Therapeutics (NASDAQ: CLDX): Plenty of Cash and Pending Clinical Catalysts

Tue, 20 Oct 2009 02:19:35 GMT

At the beginning of the month, Celldex Therapeutics (NASDAQ: CLDX) announced the successful completion of its acquisition of CuraGen (formerly CRGN), which strengthens the balance sheet (approx. $85 million in cash / equivalents) while expanding the pipeline and increasing the expected news flow of clinical data catalysts for the combined entity[More...]

The Next Big Thing In Health Care: How To Profit From Immunotherapy & Regenerative Medicine

Wed, 07 Oct 2009 19:22:50 GMT

The procedure has been called "one of the most barbaric mistakes ever perpetrated by mainstream medicine." Back when medicine was highly primitive, the process involved shoving an ice pick-like instrument between the upper eyelid and the eye in hopes of severing certain nerves of the frontal lobe.[More...]

New Jersey index reaches a yearly high

Sun, 22 Nov 2009 21:03:00 GMT

Nov. 22--The Asbury Park Press/Bloomberg 75 index reached a yearly high last Wednesday and ended the week up .28 percent.
The index, made up of 75 companies either headquartered at the Shore or with significant operations in New Jersey, was at 108.92 Friday at 5 p.m., up .3 points.
The index has risen 13.1 percent since the beginning of the year.

: iStockAnalyst.com Symbols Feed

A Busy Month For Immunogen (Part II)

Invest In HealthCare!

Most Active Stock Options November 18, 2009 & Trading Activity

Options Intelligence Report: Mead Johnson And Bristol Myers Split Inspires Option Traders

Investing In The Biotech Sector: Here’s An Easy Way To Profit From Biotech Stocks

Big Pharma And Biotech - Industry Outlook

Sanofi-Aventis to Create China Vitamin JV with Minsheng

Healthcare M&A Activitiy: Three Healthcare Small Caps Primed For Takeovers

Celldex Therapeutics (NASDAQ: CLDX): Plenty of Cash and Pending Clinical Catalysts

The Next Big Thing In Health Care: How To Profit From Immunotherapy & Regenerative Medicine

New Jersey index reaches a yearly high

Earnings Preview: Bristol-Myers 3Q earnings report

Chicago Tribune Gail MarksJarvis Column: Recession's End Doesn't Make Stock Picking Easy

Daily Mail, London, Market Report Column

Evening Standard, London, Market Report Column

UPI NewsTrack Business

Onglyza approved for Type 2 Diabetes

Astra 2Q profit up 6 pct as it cuts costs

Home Sales, Earnings Reports Ignite Markets

Dow tops 9,000 as home sales rise for 3rd month

Rothman Research Issues Fundamental Research on Players in the Financial, Healthcare & Services Sectors

PicksThatMove.com Announces Investment Opinion on Bristol-Myers Squibb Co., Incyte Corp., EnCana Corporation, B2Gold Corp. and Medclean Technologies Inc.

Bristol-Myers Squibb Announces Split-Off of Mead Johnson

AMRI Announces Third Quarter 2009 Results

Bristol-Myers Squibb Achieves Strong Sales, Earnings Performance in Third Quarter

Mead Johnson Reports Solid Third Quarter Results; Narrows Full-Year 2009 Guidance to Top End of Range

Bristol-Myers Squibb Announces Dividend

Bristol-Myers Squibb Completes Acquisition of Medarex, Inc.

Bristol-Myers Squibb Completes Initial Tender Offer for Medarex, Inc. With 87.7% of Shares Tendered; Announces Subsequent Offering Period

Bristol-Myers Squibb Extends Tender Offer for Medarex, Inc.

Form 4 MCBRIDE ANTHONY A For: Nov 01 (10K)

Form 4 Williams R Sanders For: Sep 30 (10K)

Form 4 WEST TOGO D JR For: Sep 30 (10K)

Form 4 GROBSTEIN MICHAEL For: Sep 30 (10K)

Form 4 HOOPER ANTHONY C For: Sep 21 (10K)

Form 4 SIGAL ELLIOT For: Sep 21 (10K)

Form 4 ANDREOTTI LAMBERTO For: Sep 21 (10K)

Form 4 Zito Robert T For: Aug 02 (10K)

Form 4 WEST TOGO D JR For: Jun 30 (10K)

Form 4 GROBSTEIN MICHAEL For: Jun 30 (10K)